Track topics on Twitter Track topics that are important to you
Cambridge, UK, 6 March 2017 - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that one of the ‘Abzena inside’ Composite Human Antibody™ products previously disclosed as being in Phase I trials is moving forwards into a Phase II clinical trial.
The product is being developed by an un-named major US pharmaceutical company for the treatment of neurodegenerative conditions and has been studied to date in two Phase I clinical trials.
Dr John Burt, Abzena’s CEO, said:
“We are pleased to see the progression of this ‘Abzena inside’ product into Phase II clinical development following the recent similar announcements about two other ‘Abzena inside’ products. This illustrates the strength we have in the portfolio of products that our partners are developing based on our antibody engineering technology.”
Notes To Editors
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
The term “Abzena inside” is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on “Abzena inside” products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).
For more information, please see www.abzena.comFor more information please contact: Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer Instinctif Partners Melanie-Toyne Sewell / Rozi Morris / Alex Shaw +44 1223 903498 +44 20 7457 2020 firstname.lastname@example.orgNEXT ARTICLE
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...